Hypertension and cardiovascular diseases related to it remain the leading medical challenges globally. Several drugs have been synthesized and commercialized to manage hypertension. Some of these drugs have a dihydropyrimidine skeleton structure, act as efficient calcium channel blockers, and affect the calcium ions’ intake in vascular smooth muscle, hence managing hypertension. The synthesis of such moieties is crucial, and documenting their structure–activity relationship, their evolved and advanced synthetic procedures, and future opportunities in this area is currently a priority. Tremendous efforts have been made after the discovery of the Biginelli condensation reaction in the synthesis of dihydropyrimidines. From the specific selection of Biginelli adducts to the variation in the formed intermediates to achieve target compounds containing heterocylic rings, aldehydes, a variety of ketones, halogens, and many other desired functionalities, extensive studies have been carried out. Several substitutions at the C3, C4, and C5 positions of dihydropyrimidines have been explored, aiming to produce feasible derivatives with acceptable yields as well as antihypertensive activity. The current review aims to cover this requirement in detail.

Background: Patient adherence to insulin therapy is one of the major challenges during the treatment of diabetes mellitus. Considering the dearth of investigations, this study aimed to determine the adherence pattern and factors linked with nonadherence among diabetic patients using insulin in Al-Jouf region of Saudi Arabia. Methods: This cross-sectional study included diabetic patients using basal-bolus regimens, whether they had type 1 or type 2 diabetes. This study’s objective was determined using a validated data collection form that included sections on demographics, reasons for missed insulin doses, list of barriers to therapy, difficulties during insulin administration, and factors that may improve insulin inaction adherence. Results: Of 415 diabetic patients, 169 (40.7%) were reported to forget doses of insulin every week. The majority of these patients (38.5%) forget one or two doses. Away from home (36,1%), inability to adhere to the diet (24.3%) and embarrassment to administer injections in public (23.7%) were frequently cited as reasons for missing insulin doses. The occurrence of hypoglycemia (31%), weight gain (26%), and needle phobia (22%) were frequently cited as obstacles to insulin injection use. Preparing injections (18.3%), using insulin at bedtime (18.3%), and storing insulin at a cold temperature (18.1%) were the most challenging aspects of insulin use for patients. Reduction in the number of injections (30.8%) and convenient timing for insulin administration (29.6%) were frequently cited as factors that may improve participant adherence. Conclusions: This study revealed that the majority of diabetic patients forget to inject insulin, primarily as a result of travel. By identifying potential obstacles faced by patients, these findings direct health authorities to design and implement initiatives to increase insulin adherence among patients.

Erucic acid is a monounsaturated omega-9 fatty acid with reported immunomodulatory activity. This study evaluated its protective effects against cyclophosphamide (CTX)-induced immunosuppression in mice. Thirty animals were divided into six groups: normal control, CTX (80 mg kg⁻¹), erucic acid (10 and 20 mg kg⁻¹), levamisole (20 mg kg⁻¹), and an erucic acid-only group (20 mg kg⁻¹). Immune organ indices, hematological parameters, cytokines, oxidative stress markers, IgG levels, and splenic lymphocyte proliferation were measured, along with histological assessment of the spleen and thymus. Network pharmacology was used to predict immune-related targets and docking affinities. CTX reduced the spleen index from 7.26 ± 0.75 mg g⁻¹ to 3.04 ± 0.21 mg g⁻¹ and the thymus index from 3.60 ± 0.32 mg g⁻¹ to 1.50 ± 0.21 mg g⁻¹. Lymphocyte proliferation dropped from 100.0 ± 3.28% to 37.50 ± 3.07%. WBC and RBC counts declined to 2.53 ± 0.30 × 10³ µL⁻¹ and 4.33 ± 0.69 × 10⁶ µL⁻¹, respectively. CTX also lowered IFN-γ (3.50 ± 0.19 to 1.80 ± 0.19 ng mg⁻¹), TNF-α (105.0 ± 5.56 to 52.0 ± 5.56 pg mL⁻¹), and IgG levels (12.00 ± 0.54 to 4.70 ± 0.54 pg mL⁻¹), while increasing MDA (1.42 ± 0.16 to 4.88 ± 0.41 nmol mg⁻¹) and NO (0.10 ± 0.01 to 0.24 ± 0.01 µmol g⁻¹). Erucic acid at a 20 mg kg⁻¹ dose increased the spleen index to 6.63 ± 0.60 mg g⁻¹, the thymus index to 3.00 ± 0.22 mg g⁻¹, and the lymphocyte proliferation to 61.67 ± 3.44%. It improved WBC counts to 4.72 ± 0.29 × 10³ µL⁻¹ and restored IFN-γ (3.28 ± 0.22 ng mg⁻¹), TNF-α (87.0 ± 5.56 pg mL⁻¹), and IgG (9.03 ± 0.87 pg mL⁻¹). Antioxidant markers also improved, with SOD rising from 5.55 ± 0.52 to 10.22 ± 1.02 U mg⁻¹ and GSH from 3.13 ± 0.35 to 6.45 ± 0.46 µmol g⁻¹. Histology showed reduced splenic and thymic damage in treated groups. Docking analysis indicated strong interactions between erucic acid and key immune-regulatory targets. Overall, erucic acid, particularly at a dose of 20 mg kg⁻¹, counteracted cyclophosphamide-induced immune suppression and oxidative stress, with effects comparable to those of levamisole.